Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk is a company that I really want to own - but not unless it's offered at an appealing price. Doesn't have to be bargain-like - just better. I've written about the company twice in the past, both times taking a neutral stance. The latest stance was the right one to take. The company has underperformed.

Novo Nordisk: Some Changes, But No Changes In Thesis

Novo Nordisk said it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.

Novo Nordisk to increase manufacturing capacity of weight-loss drugs

Danish drugmaker Novo Nordisk raised its full-year earnings outlook on strong sales of diabetes treatment Ozempic, also reporting a better-than-expected profit.

Novo Nordisk sees faster profit growth on demand for diabetes drug Ozempic

Danish pharmaceutical company Novo Nordisk AS NOVO.B, -2.21% NVO, -2.21% on Wednesday raised full-year guidance and reported a third-quarter net profit that beat expectations amid strong demand for its diabetes care and obesity treatments.

Novo Nordisk lifts guidance as earnings beat expectations

Financial report for the period 1 January 2022 to 30 September 2022

Novo Nordisk's sales increased by 26% in Danish kroner and by 16% at constant exchange rates to DKK 128.9 billion in the first nine months of 2022

Bayer AG

BAYRY vs. NVO: Which Stock Is the Better Value Option?

BAYRY or NVO: Which Is the Better Value Stock Right Now?

ISSOIRE, France--(BUSINESS WIRE)-- #digitalhealth--Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME) (Paris:ALCOR), a French company specialized in the design, development, and manufacturing of innovative medical devices, announces the signature of a partnership agreement with Novo Nordisk for the commercialization of Mallya, initially in Japan.

BIOCORP and NOVO NORDISK Strengthen Their Partnership With a New Agreement on Mallya® Smart Sensor

It would be a major addition to an already rich portfolio.

Prediction: This Could Be This Company's Next Billion-Dollar Product

Forma Therapeutics Holdings

Bagsværd, Denmark, 14 October 2022 – Novo Nordisk today announced that the acquisition of Forma Therapeutics Holdings, Inc. (Forma), announced on 1 September 2022, has been completed.

Novo Nordisk announces the completion of the Forma Therapeutics acquisition

Akero Therapeutics Inc

Amgen

Biogen

bluebird bio

Chemocentryx

iShares Nasdaq Biotechnology ETF

Karuna Therapeutics Inc

Pfizer

Rhythm Pharmaceuticals

SPDR S&P Biotech ETF

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

Novo Nordisk (NVO) expects new acquisitions to diversify its portfolio of marketed drugs and help combat the stiff competition in the diabetes market.

Will Acquisitions Help Novo Nordisk (NVO) Combat Stiff Rivalry?

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, Inc., a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop small molecule therapeutics across a broad range of diseases, announced today that the company has entered into an exclusive worldwide license agreement with Novo Nordisk A/S to develop and commercialize candidates from Ventus' portfolio of peripherally-restricted NLRP3 inhibitors. “This is an i

Ventus Therapeutics Enters Exclusive Development and License Agreement with Novo Nordisk for NLRP3 Inhibitor Program

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Forma Therapeutics, Holdings Inc. (NasdaqGM: FMTX) to Novo Nordisk A/S (NYSE: NVO). Under the terms of the proposed transaction, shareholders of Forma will receive $20 in cash for each share of Forma that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequa

FORMA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

BERKELEY, Calif.--(BUSINESS WIRE)--Carmot Therapeutics, Inc. (Berkeley, CA), a clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer, announced today an expansion of its Board of Directors and executive leadership team. Anne Phillips, MD, FRCPC joins Carmot's Board and Heather Turner, J.D., joins as Chief Operating Officer. “We are delighted to welcome Anne P

Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO

Bagsværd, Denmark and Redmond , W A , US , 12 September 2022 – Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft's computational services, cloud and artificial intelligence (AI) with Novo Nordisk's drug discovery, development and data science capabilities.

Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence

FORMA THERAPEUTICS INVESTOR ALERT by The Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forma Therapeutics, Holdings Inc. - FMTX

Novo Nordisk (NVO) inks agreement to acquire Forma Therapeutics for $1.1 billion. The company is looking to venture into the sickle cell disease and rare blood disorders space.

Novo Nordisk (NVO) to Tap Into SCD Space With Forma Acquisition

NEW YORK , Sept. 1, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Forma Therapeutics Holdings, Inc. ("Forma Therapeutics" or the "Company") (NASDAQ: FMTX), in connection with the proposed acquisition of the Company by Novo Nordisk A/S (NYSE: NVO) via tender offer.

SHAREHOLDER ALERT: Weiss Law Investigates Forma Therapeutics Holdings, Inc.

Novo Nordisk said Thursday it will spend $1.1 billion to acquire Forma in a deal that sent biotech stock Forma flying. The post Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout appeared first on Investor's Business Daily.

Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout

It's a newsworthy morning as Novo Nordisk (NYSE: NVO ) just announced that it will acquire Forma Therapeutics (NASDAQ: FMTX ). This is a $1.1 billion deal that will allow Novo Nordisk to expand its portfolio of blood disorder treatments.

Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News

Novo Nordisk (NYSE: NVO) is buying Forma Therapeutics, Holdings Inc (Nasdaq: FMTX) for $1.1 billion. This is why.

Why Novo Nordisk (NVO) Is Buying Forma Therapeutics (FMTX) For $1.1 Billion

Danish drugmaker Novo Nordisk will acquire Forma Therapeutics in a deal valued at $1.1 billion to expand its rare blood disorders portfolio, the companies said on Thursday.

Novo Nordisk to acquire Forma Therapeutics in $1.1. billion deal

Forma Therapeutics Holdings Inc. FMTX, +1.67% announced Thursday and agreement to be acquired by Denmark-based Novo Nordisk NVO, +0.06% NOVO.B, -0.59% in a deal with an equity value of $1.1 billion. Forma shares are halted for news until 8:30 a.m.

Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion

Eli Lilly

Given that less than 3% of the 110 million obese Americans are being treated with drugs, new medications from Novo Nordisk AS ( NVO , Financial) and Eli Lilly and Co. ( LLY , Financial) could fatten the bottom line of both companies along with their share prices.

Novo Nordisk, Eli Lilly Could Fatten Up on Weight-Loss Treatments

Albertsons Companies

Dollar General

The notion of a looming housing market crash appears to be picking up steam. There are multiple signs the ongoing correction could morph into something worse.

News for Novo Nordisk Stock (NVO)